The Eurofins Network Expands Its Offering in Renal and Transplant Testing in the United States With the Acquisition of Ascend Clinical LLC
2024年4月3日 - 2:15PM
ビジネスワイヤ(英語)
Regulatory News:
Eurofins Scientific (EUFI.PA), a global leader in bioanalytical
testing, announces the closing of its acquisition of Ascend
Clinical, LLC (“Ascend”), the largest independent laboratory for
kidney dialysis testing in the United States. Founded in 2000,
Ascend operates a state-of-the-art laboratory in Sunnyvale,
California and employs 170 staff. The company provides highly
automated chemistry, hematology, microbiology and virology testing
services to dialysis clinics and hospitals across the United
States. The company also offers water and dialysate testing,
providing greater safety to the dialysis patient community and
facilitating successful regulatory audits and surveys. Ascend’s
core competencies and client relationships complement the Eurofins
network’s extensive portfolio of pre- and post-transplant services,
which will result in better and broader service offerings to
clients.
The acquisition further reinforces the Eurofins network’s
footprint in transplant testing and associated renal care,
broadening its clinical client base. Ascend, in return, gains
access to Eurofins' extensive laboratory network, analytical
portfolio, and established industry relationships. Patti Hunsader,
the current COO of Ascend, will assume the role of President of
Ascend Clinical. The existing leadership of the company will remain
in place, continuing to drive the organisation’s growth as part of
the Eurofins clinical diagnostics business line in the United
States.
Comment from Dr. Gilles Martin, Eurofins CEO: "This transaction
further extends our efforts to provide best in class testing care
to patients in the renal and transplantation fields. We look
forward to providing Ascend’s clients with access to the
capabilities of the Eurofins network, and to support Ascend in
strengthening and growing the important services they provide to
patients.”
Comment from Patti Hunsader, Ascend COO: "We are excited to join
forces with the Eurofins network. This partnership creates exciting
opportunities to leverage our combined expertise and resources to
positively impact the lives of the patients we serve."
Integrating Ascend's expertise and client base with Eurofins'
geographic reach, technological capabilities and expertise will
elevate the standard of care provided for patients nationwide.
Notes to Editors:
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. The Eurofins Scientific S.E.
network of independent companies believes that it is a global
leader in food, environment, pharmaceutical and cosmetic product
testing and in discovery pharmacology, forensics, advanced material
sciences and agroscience contract research services. It is also one
of the market leaders in certain testing and laboratory services
for genomics, and in the support of clinical studies, as well as in
biopharma contract development and manufacturing. It also has a
rapidly developing presence in highly specialised and molecular
clinical diagnostic testing and in-vitro diagnostic products.
With ca. 62,000 staff across a decentralised and entrepreneurial
network of more than 900 laboratories in over 1,000 companies in 62
countries, Eurofins offers a portfolio of over 200,000 analytical
methods to evaluate the safety, identity, composition,
authenticity, origin, traceability and purity of a wide range of
products, as well as providing innovative clinical diagnostic
testing services and in-vitro diagnostic products.
Eurofins companies’ broad range of services are important for
the health and safety of people and our planet. The ongoing
investment to become fully digital and maintain the best network of
state-of-the-art laboratories and equipment supports our objective
to provide our customers with high-quality services, innovative
solutions and accurate results in the best possible turnaround time
(TAT). Eurofins companies are well positioned to support clients’
increasingly stringent quality and safety standards and the
increasing demands of regulatory authorities as well as the
evolving requirements of healthcare practitioners around the
world.
The Eurofins network has grown very strongly since its inception
and its strategy is to continue expanding its technology portfolio
and its geographic reach. Through R&D and acquisitions, its
companies draw on the latest developments in the field of
biotechnology and analytical chemistry to offer their clients
unique analytical solutions.
Shares in Eurofins Scientific S.E. are listed on the Euronext
Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg
ERF FP).
About Ascend
Ascend Clinical was founded in Northern California in 2000 as a
clinical reference laboratory specializing in testing services for
kidney disease. Ascend’s dedication to advanced technology and
innovative solutions has expanded their services to cover a wide
range of in vitro diagnostics. With a state-of-the-art laboratory
located in Sunnyvale, CA, and offices in Colorado, Ascend is one of
the largest independent labs in the United States, committed to
supporting clinicians and enhancing patient care. More information
at www.aclab.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240402530392/en/
For more information, please visit www.eurofins.com or
contact: Investor Relations Eurofins Scientific SE Phone: +32 2
766 1620 E-mail: ir@sc.eurofinseu.com
Enerplus (NYSE:ERF)
過去 株価チャート
から 9 2024 まで 10 2024
Enerplus (NYSE:ERF)
過去 株価チャート
から 10 2023 まで 10 2024